Tyra Biosciences, Inc.

NASDAQ:TYRA

Biotechnology

Healthcare
$19.61 -2.48%

-$0.72 today

Market cap
$1.35B
Beta
0.75
P/E (TTM)
-13.4
EPS (TTM)
-$2.12
52W Low $8.98High $40.65

Volume 0.47M

Average 0.96M

TYRA EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Tyra Biosciences, Inc.NASDAQ: TYRA

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$39.17M, compared with -$28M a year earlier. Trailing-twelve-month EBITDA was -$130.56M.

Context

  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 7 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -38.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$39.17M-16.2% QoQ
Last fiscal yearDec 2025
-$119.4M-38.9% YoY
LTMMar 2026
-$130.56M-36.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-39.9%+100.0%+139.9 pp
1 year-38.9%+100.0%+138.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(119.4M) USD
Year-over-year change
-38.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How TYRA compares with its peers on the latest reported figures

  • TYRA's LTM Mar 2026 EBITDA of -$130.56M is the 5th highest of the 11 companies compared; the peer median is -$139.63M.
  • Its year-over-year change of -36.2% is the 8th highest of 11, against a peer median of -18.9%.
TYRA Competitors Peer median
EBITDA for TYRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026-$50.64M -7.0%—32.2%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-$72.53M +7.7%—257.0%
JANXJanux Therapeutics, Inc.LTM Mar 2026-$112.45M -48.6%—520.3%
NUVBNuvation Bio Inc.LTM Jun 2026-$127.04M +36.8%—74.8%
TYRATyra Biosciences, Inc.LTM Mar 2026-$130.56M -36.2%——
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026-$134.03M -1.8%——
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026-$145.24M -14.0%——
BCAXBicara Therapeutics Inc. Common StockLTM Mar 2026-$156.99M -70.6%——
VSTMVerastem, Inc.LTM Mar 2026-$191.95M -32.3%—387.1%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026-$220.73M -23.8%——
KURAKura Oncology, Inc.LTM Mar 2026-$292.27M -64.2%—408.0%
Peer median (excluding TYRA) -$139.63M-18.9%—322.1%

Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development20.64M43.01M62.52M80.08M102.93M
Selling, General & Admin5.65M15.92M17.43M24.1M29.83M
Operating Expenses26.29M58.93M79.95M104.18M132.76M
Depreciation & Amortization140K296K357K519K546K
EBITDA(26.15M)(55.03M)(68.78M)(85.96M)(119.4M)
EBITDA Margin—————
Operating Income(26.29M)(58.93M)(79.95M)(104.18M)(132.76M)
Operating Margin—————
Interest Income13K3.65M10.81M17.7M12.82M
Interest Expense00000
Other Income / Expenses(6K)3.6M10.81M17.7M12.82M
Income Before Tax(26.29M)(55.33M)(69.13M)(86.48M)(119.95M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(26.29M)(55.33M)(69.13M)(86.48M)(119.95M)
Net Margin—————
EPS (Basic)(0.63)(1.23)(1.62)(1.51)(2.01)
EPS (Diluted)(0.63)(1.23)(1.62)(1.51)(2.01)
Weighted Avg Shares41.44M41.88M42.7M57.22M59.6M
Weighted Avg Shares (Diluted)41.44M41.88M42.7M57.22M59.6M

Tyra Biosciences, Inc.

NASDAQ:TYRA

Intrinsic Alpha fair value

Locked

Current Price

$19.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.